Cullinan Therapeutics, Inc. (CGEM) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2023
Loading P/E history...
CGEM Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
The current P/E is 166% below its 5-year average of 6.0x. Over the past five years, CGEM's P/E has ranged from a low of 4.5x to a high of 8.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CGEM trades at a 118% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CGEM trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CGEM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CGEM P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $39B | 127.0Lowest | -Best | +207%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CGEM Historical P/E Data (2022–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $10.23 | $1.22 | 8.4x | +40% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $10.55 | $2.37 | 4.5x | -26% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $12.82 | $2.22 | 5.8x | -4% |
| FY2022 Q2 | $12.82 | $2.36 | 5.4x | -10% |
Average P/E for displayed period: 6.0x
See CGEM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGEM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CGEM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCGEM — Frequently Asked Questions
Quick answers to the most common questions about buying CGEM stock.
Is CGEM stock overvalued or undervalued?
CGEM trades at -4.0x P/E, below its 5-year average of 6.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CGEM's valuation compare to peers?
Cullinan Therapeutics, Inc. P/E of -4.0x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CGEM's PEG ratio?
CGEM PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2023.